SymBio Pharmaceuticals Limited
Notice Regarding Borrowing of Funds
Executed borrowings to fund working capital and research and development. Lenders are Mr. Fuminori Yoshida and Ms. Ikuko Yoshida, amounts of 340 hundred million yen and 175 hundred million yen respectively; repayment in full on December 30, 2026; unsecured; interest rate 0.0%. No impact on consolidated results for the fiscal year ending December 2026.
Key Figures
- Borrowing Amount: 340,000,000 yen (interest rate 0.0%)
- Borrowing Amount: 175,000,000 yen (interest rate 0.0%)
- Repayment Date: 2026-12-30
AI要約
Key Points of Financing
This report discloses new borrowings to secure funds necessary for business execution, including working capital and research and development expenses. The lenders are individuals, with amounts of 340 hundred million yen and 175 hundred million yen, both at an annual interest rate of 0.0%, repayable in a lump sum on the maturity date, unsecured. The execution and signing date is October 15, 2026, and the repayment date is December 30, 2026. It is stated that this matter will not affect consolidated results for the fiscal year ending December 2026.
Impact on Investors and Outlook
This is short-term financing, and while cash position fluctuations may occur as the repayment date approaches, the view is that there will be no impact on performance. The funds are intended for working capital and research and development, and can be interpreted as aimed at improving liquidity flexibility. The long-term effect on capital efficiency is unknown, so future disclosures should be monitored.
SymBio Pharmaceuticals Limited
Company overview · Stock price · Financial data · All IR
